Article
Respiratory System
Timothy M. Dempsey, Stephanie Payne, Lindsey Sangaralingham, Xiaoxi Yao, Nilay D. Shah, Andrew H. Limper
Summary: Since their approval in 2014, the adoption of pirfenidone and nintedanib in the United States has been low, which may be associated with the high out-of-pocket costs.
ANNALS OF THE AMERICAN THORACIC SOCIETY
(2021)
Article
Biochemistry & Molecular Biology
Shih-Lung Cheng, Chau-Chyun Sheu, Chih-Feng Chian, Jeng-Yuan Hsu, Kuo-Chin Kao, Liang-Wen Hang, Ching-Hsiung Lin, Wen-Feng Fang, Hao-Chien Wang, Diahn-Warng Perng
Summary: This study is the first registry in Taiwan to observe the progression of idiopathic pulmonary fibrosis (IPF) under routine clinical practice. The findings indicate that antifibrotic medication is beneficial in delaying IPF progression, reducing acute exacerbations, and delaying mortality.
Review
Critical Care Medicine
Tananchai Petnak, Ploypin Lertjitbanjong, Charat Thongprayoon, Teng Moua
Summary: Meta-analysis of 26 studies showed that antifibrotic treatment reduced the risk of all-cause mortality and acute exacerbations in patients with idiopathic pulmonary fibrosis (IPF).
Article
Cardiac & Cardiovascular Systems
Takuma Isshiki, Susumu Sakamoto, Akira Yamasaki, Hiroshige Shimizu, Shion Miyoshi, Yasuhiko Nakamura, Sakae Homma, Kazuma Kishi
Summary: The study found that the incidence of AE-IPF was lower in IPF patients receiving antifibrotic agents, with a lower incidence in the pirfenidone group compared to the nintedanib group. The survival rates after AE-IPF onset were similar between the two groups.
RESPIRATORY MEDICINE
(2021)
Article
Engineering, Biomedical
Binghua Wang, Yiwen Gao, Lulu Sun, Meng Xue, Mingjin Wang, Zhenzhong Zhang, Lirong Zhang, Hongling Zhang
Summary: Idiopathic pulmonary fibrosis (IPF) is a deadly lung disease with limited treatment options. Researchers have developed a new drug delivery system using nano-biomimetic liposomes to target damaged lung cells and reduce lung tissue clearance. In vivo results show promising therapeutic effects in mice with IPF, offering potential benefits for patients.
Article
Cardiac & Cardiovascular Systems
Simon Porse, Nils Hoyer, Saher B. Shaker
Summary: This study aimed to investigate the impact of antifibrotic treatment reduction on death in idiopathic pulmonary fibrosis (IPF) patients. The results showed that reducing the dosage of antifibrotic drugs, such as nintedanib and pirfenidone, in IPF patients did not lead to worse survival outcomes. In fact, treatment with these drugs, regardless of the dosage, was associated with improved survival compared to no antifibrotic treatment.
RESPIRATORY MEDICINE
(2022)
Review
Biochemistry & Molecular Biology
Panagiotis Paliogiannis, Sara Solveig Fois, Alessandro Giuseppe Fois, Antonio Cossu, Giuseppe Palmieri, Gianfranco Pintus
Summary: Idiopathic pulmonary fibrosis (IPF) and lung cancer share similarities in molecular, pathophysiological, and clinical aspects, with high mortality rates. Anti-fibrotic drugs like Nintedanib and Pirfenidone have potential for treating lung cancer, while novel targeted agents and immunotherapies may have anti-fibrotic properties. This suggests the possibility of using anti-fibrotic and anti-neoplastic drugs in combination for the treatment of these deadly diseases.
CURRENT MEDICINAL CHEMISTRY
(2021)
Review
Respiratory System
James Patrick Finnerty, Aravind Ponnuswamy, Prosjenjit Dutta, Ammar Abdelaziz, Hafiz Kamil
Summary: This study compared the efficacy of nintedanib and pirfenidone in the treatment of progressive pulmonary fibrosis, finding that anti-fibrotic therapy can slow the decline in forced vital capacity in both IPF and non-IPF patients. However, there was insufficient data to confirm a reduction in mortality in non-IPF patients with anti-fibrotic therapy.
BMC PULMONARY MEDICINE
(2021)
Article
Multidisciplinary Sciences
Jieun Kang, Jin Woo Song
Summary: The study found that the addition of sildenafil to antifibrotic treatment did not significantly impact the clinical outcomes of patients with IPF.
SCIENTIFIC REPORTS
(2021)
Article
Medicine, Research & Experimental
Saba Noor, Saira Nawaz, Nazia Chaudhuri
Summary: This study evaluated the impact of antifibrotic therapy in IPF patients with preserved lung function based on a FVC above 80%. Results showed that antifibrotic therapy was associated with a significantly higher median survival rate in patients compared to those who did not receive treatment.
ADVANCES IN THERAPY
(2021)
Article
Cardiac & Cardiovascular Systems
Zachariah L. Dorey-Stein, William Shapiro, Huaqing Zhao, Francis C. Cordova, Gerard J. Criner, Jonathan A. Galli
Summary: The study showed that IPF patients on antifibrotic therapy before lung transplantation had better preservation of lung function in the pre-transplant period, and similar outcomes in the postoperative period compared to those not on antifibrotic therapy before lung transplant.
RESPIRATORY MEDICINE
(2021)
Article
Multidisciplinary Sciences
Yuzo Suzuki, Kazutaka Mori, Yuya Aono, Masato Kono, Hirotsugu Hasegawa, Koshi Yokomura, Hyogo Naoi, Hironao Hozumi, Masato Karayama, Kazuki Furuhashi, Noriyuki Enomoto, Tomoyuki Fujisawa, Yutaro Nakamura, Naoki Inui, Hidenori Nakamura, Takafumi Suda
Summary: The study evaluated the significance of the GAP index and BMI in predicting prognosis in patients with IPF receiving AFT.
SCIENTIFIC REPORTS
(2021)
Article
Pharmacology & Pharmacy
Meishan Han, Yingjian Song, Sha Liu, Xiaoyan Lu, Linyu Su, Meixuan Liu, Xiaosu Zhu, Kaoxiang Sun, Yanan Lu, Aiping Wang
Summary: Idiopathic pulmonary fibrosis is a challenging lung disease without effective drug treatments. Pirfenidone pH-sensitive liposomes show promise in targeting IPF with reduced side effects and improved efficacy.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Medicine, General & Internal
Luca Richeldi, Arata Azuma, Vincent Cottin, Christian Hesslinger, Susanne Stowasser, Claudia Valenzuela, Marlies S. Wijsenbeek, Donald F. Zoz, Florian Voss, Toby M. Maher
Summary: This double-blind, placebo-controlled trial showed that treatment with BI 1015550, either alone or with background use of an antifibrotic agent, prevented a decrease in lung function in patients with idiopathic pulmonary fibrosis.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Yuji Iwanami, Kento Ebihara, Keiko Nakao, Naofumi Sato, Midori Miyagi, Yasuhiko Nakamura, Susumu Sakamoto, Kazuma Kishi, Sakae Homma, Satoru Ebihara
Summary: This study investigated the effect of pulmonary rehabilitation (PR) on patients with idiopathic pulmonary fibrosis (IPF) receiving antifibrotic drugs (AFDs). The results showed that PR can improve dyspnea and exercise tolerance, and may prevent or mitigate the side effects of AFDs.
JOURNAL OF CLINICAL MEDICINE
(2022)
